AEMD Q3 operating expenses rise 13.6% to USD 2.06 million

Reuters

Feb 13

AEMD Q3 operating expenses rise 13.6% to USD 2.06 million

Aethlon Medical Inc. reported its financial results for the third quarter (Q3) ended December 31, 2025. The company posted consolidated operating expenses of approximately 2.06 million ISO, reflecting a 13.6% increase, primarily due to higher payroll expenses. As of December 31, 2025, Aethlon Medical held a cash balance of about 7.0 million ISO. Total stockholders’ equity stood at 6.71 million ISO at the end of the period, while total liabilities and stockholders’ equity amounted to 8.06 million ISO. The accumulated deficit was 173.22 million ISO. Operationally, Aethlon Medical achieved a 26.9% reduction in operating expenses during the nine months ended December 31, 2025, as part of ongoing cost optimization efforts while advancing clinical and research programs. The company continues to focus on developing products targeting cancer and life-threatening infectious diseases, with CEO and CFO James Frakes highlighting recent progress in trials, research collaborations, and technology development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA86076) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611970482"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611970482\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611970482?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611970482","market":"nz","top_or_hot":-1,"title":"AEMD Q3 operating expenses rise 13.6% to USD 2.06 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AEMD Q3 operating expenses rise 13.6% to USD 2.06 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. reported its financial results for the third quarter (Q3) ended December 31, 2025. The company posted consolidated operating expenses of approximately 2.06 million ISO, reflecting a 13.6% increase, primarily due to higher payroll expenses. As of December 31, 2025, Aethlon Medical held a cash balance of about 7.0 million ISO. Total stockholders’ equity stood at 6.71 million ISO at the end of the period, while total liabilities and stockholders’ equity amounted to 8.06 million ISO. The accumulated deficit was 173.22 million ISO. Operationally, Aethlon Medical achieved a 26.9% reduction in operating expenses during the nine months ended December 31, 2025, as part of ongoing cost optimization efforts while advancing clinical and research programs. The company continues to focus on developing products targeting cancer and life-threatening infectious diseases, with CEO and CFO James Frakes highlighting recent progress in trials, research collaborations, and technology development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA86076) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AEMD Q3 operating expenses rise 13.6% to USD 2.06 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAEMD Q3 operating expenses rise 13.6% to USD 2.06 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AEMD Q3 operating expenses rise 13.6% to USD 2.06 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. reported its financial results for the third quarter (Q3) ended December 31, 2025. The company posted consolidated operating expenses of approximately 2.06 million ISO, reflecting a 13.6% increase, primarily due to higher payroll expenses. As of December 31, 2025, Aethlon Medical held a cash balance of about 7.0 million ISO. Total stockholders’ equity stood at 6.71 million ISO at the end of the period, while total liabilities and stockholders’ equity amounted to 8.06 million ISO. The accumulated deficit was 173.22 million ISO. Operationally, Aethlon Medical achieved a 26.9% reduction in operating expenses during the nine months ended December 31, 2025, as part of ongoing cost optimization efforts while advancing clinical and research programs. The company continues to focus on developing products targeting cancer and life-threatening infectious diseases, with CEO and CFO James Frakes highlighting recent progress in trials, research collaborations, and technology development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA86076) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL2Y7Csx:1","article_id":"2611970482","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611970482","pubTimestamp":1770931016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aethlon Medical Inc. reported its financial results for the third quarter  ended December 31, 2025. The company posted consolidated operating expenses of approximately 2.06 million ISO, reflecting a 13.6% increase, primarily due to higher payroll expenses. As of December 31, 2025, Aethlon Medical held a cash balance of about 7.0 million ISO. Total stockholders’ equity stood at 6.71 million ISO at the end of the period, while total liabilities and stockholders’ equity amounted to 8.06 million ISO. The accumulated deficit was 173.22 million ISO. Operationally, Aethlon Medical achieved a 26.9% reduction in operating expenses during the nine months ended December 31, 2025, as part of ongoing cost optimization efforts while advancing clinical and research programs. The company continues to focus on developing products targeting cancer and life-threatening infectious diseases, with CEO and CFO James Frakes highlighting recent progress in trials, research collaborations, and technology develo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4583":"猴痘概念","BK4082":"医疗保健设备","AEMD":"Aethlon Medical Inc"},"translate_title":"AEMD第三季度运营费用增长13.6%至206万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEMD":0.9},"content_text":"AEMD Q3 operating expenses rise 13.6% to USD 2.06 million\n    \n\nAethlon Medical Inc. reported its financial results for the third quarter (Q3) ended December 31, 2025. The company posted consolidated operating expenses of approximately 2.06 million ISO, reflecting a 13.6% increase, primarily due to higher payroll expenses. As of December 31, 2025, Aethlon Medical held a cash balance of about 7.0 million ISO. Total stockholders’ equity stood at 6.71 million ISO at the end of the period, while total liabilities and stockholders’ equity amounted to 8.06 million ISO. The accumulated deficit was 173.22 million ISO. Operationally, Aethlon Medical achieved a 26.9% reduction in operating expenses during the nine months ended December 31, 2025, as part of ongoing cost optimization efforts while advancing clinical and research programs. The company continues to focus on developing products targeting cancer and life-threatening infectious diseases, with CEO and CFO James Frakes highlighting recent progress in trials, research collaborations, and technology development.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA86076) on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}